Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 15/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640308 | 1.00 | ALDH1A1 (0.49) | ALDH1A1MAPK1FFAR1MTNR1ATDP1 | |
| SCHEMBL30640313 | 1.00 | ALDH1A1 (0.49) | ALDH1A1MAPK1FFAR1MTNR1ATDP1 | |
| SCHEMBL6794906 | 0.89 | MTNR1A (0.49) | ALDH1A1MAPK1FFAR1MTNR1A | |
| SCHEMBL30278166 | 0.88 | MTNR1A (0.51) | ALDH1A1MAPK1FFAR1MTNR1AALOX5 | |
| SCHEMBL24735866 | 0.88 | MTNR1A (0.51) | ALDH1A1MAPK1FFAR1MTNR1AALOX5 | |
| SCHEMBL5917897 | 0.85 | ALDH1A1 (0.53) | ALDH1A1MAPK1MTNR1ATDP1ALOX5 | |
| SCHEMBL5992714 | 0.84 | KDM4E (0.48) | ALDH1A1MAPK1MTNR1AALOX5 | |
| SCHEMBL5918015 | 0.83 | F2 (0.55) | FFAR1ALOX5 | |
| SCHEMBL5917872 | 0.83 | F2 (0.55) | FFAR1ALOX5 | |
| SCHEMBL16070939 | 0.83 | HPGD (0.47) | ALDH1A1MAPK1FFAR1MTNR1AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112079830-B | Inhibitor containing fused ring derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-112079830-A | Fused ring-containing derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2020-12-15 | — | — | CN | disclosed |
| US-6835735-B2 | Anticancer, tyrosine kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-12-28 | — | — | US | disclosed |
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | KOREAN INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | EGFR, ERBB2, ERBB4 | ALDH1A1 2951/4885MAPK1 343/4885FFAR1 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.